AN2 Therapeutics, Inc. (ANTX) is a Menlo Park, California–based clinical-stage biopharmaceutical company with no approved products and no product revenue. It develops small-molecule therapeutics from a boron chemistry platform, with programs in polycythemia vera, M. abscessus lung disease and chronic Chagas disease. On Wednesday the stock rose 22.70%, trading at $5.19 by late morning, against a prior session close of $4.23 — a gain of $0.96. The advance was unambiguously to the upside, with shares gapping higher at the open and reaching an intraday high near $5.28. Markets attributed the move to fresh attention on the company's Chagas program and the clinical timeline behind its lead candidates.
The catalyst was a company release issued before the opening bell describing positive results from two studies of AN2-502998, an oral CPSF3 inhibitor being developed as a potential cure for chronic Chagas disease. In a 28-day study in nonhuman primates with naturally acquired Trypanosoma cruzi infection, treatment produced parasite elimination in 100% of animals at exposures judged attainable in humans, and the effect was sustained through four months after dosing ended. A Phase 1 first-in-human study showed the compound was generally well tolerated at exposure levels consistent with those efficacy thresholds, with no dose-limiting toxicities.
Those findings matter because they sit at the center of the investment case. Chagas disease affects an estimated 10 million people globally, including roughly 300,000 in the United States, and there is no FDA-approved therapy for adults. Management has said it intends to initiate a Phase 2 proof-of-concept study in chronic Chagas disease late this year, in collaboration with the nonprofit Drugs for Neglected Diseases initiative, and the program would be eligible for an FDA Tropical Disease Priority Review Voucher if approved. For a company with a market capitalization of roughly $200 million and a cash position intended to fund operations into 2029, a credible step toward human efficacy data is a material re-rating event — and the stock's 2026 performance reflects that: shares remain up several hundred percent year to date.
The rally also had a clear technical component. ANTX had drifted lower through the first half of November, sliding from an intraday high of $4.90 in late October to $4.23 on Tuesday, a decline of roughly 14%. The stock had closed lower in five of the previous six sessions and sat below its 50-day moving average, which had been hovering near $4.55. Wednesday's advance cleared that level decisively, along with the 200-day average near $4.26 and the prior swing high, leaving the September highs around $6 as the next meaningful reference point. Pullbacks of that kind in thinly traded clinical-stage names are frequently followed by sharp, news-assisted reversals.
Volume confirmed the move. Roughly 74,000 shares changed hands in the first 70 minutes of trading — a pace of about 1.5 times the 50-day average daily volume of approximately 272,000 shares — suggesting genuine institutional and retail participation rather than a single thin print. The action was almost entirely idiosyncratic: there was no comparable swing among large-cap biotechnology peers, and the gain was not tied to any broad index or macro release. In practical terms, the tape reflected a single company's clinical narrative being repriced, amplified by a float of only about 22.5 million shares, which magnifies order-flow impact. Wednesday's range of roughly $4.23 to $5.28 was among the widest of the past two months.
The score runs from 0 to 100, where 0 means no meaningful news and a price move that is normal for the stock, and 100 means transformative news accompanied by an extreme, rare move. ANTX earns 53 out of 100.
The verified news was moderate in weight: positive animal efficacy and clean early-stage safety data that de-risk a Phase 2 step, but not human efficacy, approval or a partnership of transformative scale — and the underlying data package had been previously disclosed as part of the program's progression. The price behavior was the stronger component. Today's 22.70% advance was about 6.8 times the stock's average absolute daily move of 3.35% over the past 60 sessions, and no session in that window produced a larger absolute change, as the biggest prior swing was 17.1%. Strong news and an unusually large move combine into a mid-range score.
Attention now shifts to execution. Investors will look for confirmation that the Phase 2 Chagas proof-of-concept study begins on the promised late-2026 timeline, alongside progress in the polycythemia vera Phase 2 program, where early safety data are expected in the first quarter of 2027, and the investigator-initiated M. abscessus trial. Earnings reports will remain largely a cash-runway story rather than a revenue story; the company last reported a third-quarter net loss and reiterated funding into 2029. Analyst coverage is thin, with a small group of analysts carrying a consensus price target well above current levels — a signal of perceived upside that also raises the bar for disappointment. Key risks include the well-documented gap between animal models and human outcomes, regulatory and enrollment delays, dilution risk as programs expand, and the sensitivity of a low-float, pre-revenue equity to sentiment shifts.
Tickeron maintains hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. Strategies differ widely by approach, timeframe, performance metrics and the specific symbols they trade, so the lineup changes as market conditions evolve. Reviewing this page can help traders see which automated approaches are working right now before committing capital. Investors curious about systematic strategies may find it a useful starting point for further research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Indicator for ANTX moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 16 of the 19 cases the stock moved higher. This puts the odds of a move higher at 84%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on ANTX as a result. In 60 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for ANTX just turned positive on October 27, 2026. Looking at past instances where ANTX's MACD turned positive, the stock continued to rise in 25 of 30 cases over the following month. The odds of a continued upward trend are 83%.
ANTX moved above its 50-day moving average on November 18, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +11.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANTX advanced for three days, in 201 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 46 cases where ANTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
ANTX broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ANTX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.988) is normal, around the industry mean (3.592). P/E Ratio (-3.810) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ANTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology